Title of article
Onconephrology What Should the Internist Know About Targeted Therapy in Solid Tumors?
Author/Authors
El Rassy, Elie Department of Hematology- Oncology - Hotel Dieu de France Univeristy Hospital - Faculty of Medicine - Saint Joseph University, Lebanon , El Karak, Fadi Department of Hematology- Oncology - Hotel Dieu de France Univeristy Hospital - Faculty of Medicine - Saint Joseph University, Lebanon , Rizkallah, Jamale Department of Nephrology - Hotel Dieu de France Univeristy Hospital - Faculty of Medicine, Saint Joseph University, Lebanon , Chelala, Dania Department of Nephrology - Hotel Dieu de France Univeristy Hospital - Faculty of Medicine, Saint Joseph University, Lebanon
Pages
7
From page
169
To page
175
Abstract
Advances in medical oncology has led cancer patients to live longer.
Moreover, the field of molecular oncology is rapidly evolving,
new therapies emerge, and drugs are approved quickly. This has
led nephrologists to encounter new and partially unrecognized
treatments of the targeted therapy agents with kidney adverse
effects. These agents fall mainly into 2 categories affecting the
vascular endothelial growth factor and endothelial growth factor
pathways. This review covers the incidence of kidney disease
induced by these agents, pathophysiologic mechanisms, and
clinical presentation, and is the first to recommend an adequate
management for each pathophysiology.
Keywords
endothelial growth factor , kidney disease vascular endothelial growth factor , targeted therapies , nephrology , oncology
Journal title
Iranian Journal of Kidney Diseases (IJKD)
Serial Year
2016
Record number
2519311
Link To Document